StreetAlpha.app
Home › Stocks › AGIO

Agios Pharmaceuticals, Inc. (AGIO)

Healthcare
$29.89
▼ −0.86%
LAST CLOSE · NOV 17

Agios is a biopharmaceutical company that sells mitapivat and develops other medicines for rare diseases, mainly blood disorders. It last closed at $29.89 on Nov 17, down 0.86% on the day. AGIO reports earnings on Thu, Feb 11, 2027. The average 12-month price target from 3 analysts is $49.00 (+63.9% from the last close), with a high of $62.00 and a low of $35.00. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell). Over the past 90 days StreetAlpha recorded 1 whale options trade in AGIO, 0% of them bullish and 100% bearish.

AI Auto Pilots
Is AGIO in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$140.8M
+214.4% vs a year ago
Net income
−$372.9M
−264.8% margin
EPS (diluted)
−$6.31
Free cash flow
−$336.0M
−238.5% margin
Valuation
Market cap
$1.8B
59.8M shares
P/E
–
No P/E while losing money
Price to sales
12.7
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$128.5M
At Sep 30
Shareholder equity
$979.3M
Shares outstanding
59.8M
At Oct 30
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $0$0FY2021FY2022: $14.2M$14.2MFY2022FY2023: $26.8M$26.8MFY2023FY2024: $36.5M$36.5MFY2024FY2025: $54.0M$54.0MFY2025

From AGIO's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Next report
Feb 11
2027 · Time not announced
Consensus EPS forecast
-$1.11
$63.5M revenue est.
Year-ago EPS
—
Not on file
Options-implied move
—
Posted about a week before
Analyst consensus
Strong Buy
Based on 3 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
3firms
3 Buy0 Hold0 Sell
Each firm's latest rating on AGIO in the past 90 days
Average 12-month target
$49.00
▲ 63.9% upside

Based on 3 analysts who set a price target on AGIO in the past 90 days. The average target is $49.00, with a high of $62.00 and a low of $35.00, compared with the last close of $29.89.

Low $35.00Avg $49.00High $62.00
Blue marker: last close $29.89
Highest target$62.00
Average target$49.00
Lowest target$35.00
Latest rating changes
Truist SecuritiesTarget lowered
Nov 6Buy$37 → $35
HC Wainwright & Co.Target raised
Nov 6Buy$55 → $62
HC Wainwright & Co.Assumed coverage
Oct 29Buy$55
Truist SecuritiesTarget lowered
Oct 7Buy$39 → $37
B of A SecuritiesTarget raised
Sep 21Buy$46 → $50
DateFirmActionRatingPrice target
Nov 6Truist SecuritiesTarget loweredBuy$37 → $35
Nov 6HC Wainwright & Co.Target raisedBuy$55 → $62
Oct 29HC Wainwright & Co.Assumed coverageBuy$55
Oct 7Truist SecuritiesTarget loweredBuy$39 → $37
Sep 21B of A SecuritiesTarget raisedBuy$46 → $50
Loading…

Technical Analysis

AGIO · as of the Nov 17 close · updated after every close
Turning down

The stock is 11% below its 20 day and 10% below its 50 day average. It is 7% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 41). The nearest support is the swing low (Oct 30) at $29.80, and the nearest resistance the swing high (May 28) at $30.53.

Short trendBearish
Long trendNeutral
MomentumWeak
StretchNormal
VolatilityHigh, 6.0%/day
Key levels
$46.0052 week high+53.9%
$34.26100 day average+14.6%
$33.0920 day average+10.7%
$32.9550 day average+10.2%
$31.87200 day average+6.6%
$30.53Pivot R1+2.1%
$30.53Swing high (May 28)+2.1%
$29.89Last close
$29.80Swing low (Oct 30)−0.3%
$29.74Pivot−0.5%
$29.10Pivot S1−2.6%
$22.2452 week low−25.6%
Indicators
RSI (14)41.30Middle of its rangeNeutral
MACD-0.82Below its signal lineBearish
Stochastic26.8Middle of its rangeNeutral
ADX (14)20.5Weak trend
Williams %R-79.1Oversold below −80, overbought above −20Neutral
CCI (20)-75.0Oversold below −100, overbought above 100Neutral
Rate of change−4.2%Change over 10 sessionsBearish
ATR (14)$1.78Typical daily range, 6.0% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for AGIO

What happened before

See how AGIO did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow AGIO usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How AGIO has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2013.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Total alerts
1
Bullish
0
0%
Bearish
1
100%
Date span
Oct 20 – Oct 20
Loading…

See today’s whale options flow across the market →

AGIO Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲129 buying vs 96 selling
  • ▲Held by funds +2.0 pts
  • ▲Funds holding +5
  • ▲Superinvestors: 3 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding243238+2.1%
In funds' top 1036−50.0%
Held by funds112.5%110.5%+2.0 pts
New / increased34 / 9536 / 97−3.0%
Reduced / sold out67 / 2963 / 330.0%
Put/call ratio0.020.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See AGIO institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether AGIO is in one of them and how their past AGIO trades turned out.

AGIO in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered AGIO in an article yet. Here's the latest on the wider market.

AGIO Congress Trades

All congress trades →
Trades, 12 months
3
Buys
3
100%
Sells
0
0%
People
1
Last filed Sep 11
Who traded AGIO · since 2024
Latest 5 filings of 6
$1K – $15KTraded Aug 20, 2026Filed Sep 11, 2026
$1K – $15KTraded Mar 3, 2026Filed Apr 7, 2026
$1K – $15KTraded Dec 11, 2025Filed Jan 12, 2026
$1K – $15KTraded Apr 17, 2025Filed May 6, 2025
$1K – $15KTraded Jan 29, 2025Filed Feb 11, 2025
PersonTypeAmountTradedFiledDelay
Gilbert CisnerosD · CABuy$1K – $15KAug 20, 2026Sep 11, 202622 d
Gilbert CisnerosD · CABuy$1K – $15KMar 3, 2026Apr 7, 202635 d
Gilbert CisnerosD · CABuy$1K – $15KDec 11, 2025Jan 12, 202632 d
Gilbert CisnerosD · CABuy$1K – $15KApr 17, 2025May 6, 202519 d
Gilbert CisnerosD · CABuy$1K – $15KJan 29, 2025Feb 11, 202513 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About Agios Pharmaceuticals

Agios is a biopharmaceutical company that focuses on rare diseases, with a foundation in hematology, the study of blood disorders. Its lead medicine, mitapivat, is sold under the brand names AQVESME and PYRUKYND and is approved to treat anemia in adults with certain rare blood disorders. The company is also developing additional medicines for rare blood and metabolic conditions. Agios is based in Cambridge, Massachusetts, and serves patients and the clinicians who treat them.

Headquarters
Cambridge, MA
Founded
2008